Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

Patients with atopic dermatitis aged 2 years and older who used tapinarof cream 1% had significant improvements in various patient-reported outcomes.

The FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on Monday. Approval of the topical aryl hydrocarbon receptor agonist was ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

In December 2024, the FDA approved an aryl hydrocarbon receptor agonist called tapinarof cream 1 percent (Vtama) to treat atopic dermatitis in adults and children ages 2 or older. Two biologic ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a ...

EFFICACY: In the pivotal studies, ADORING 1 and ADORING 2, up to 46% of patients on VTAMA cream achieved vIGA-AD™ treatment success at Week 8 versus 18% of patients on vehicle. POWERFUL SKIN CLEARANCE ...

Nemluvio Approved for Moderate to Severe Atopic Dermatitis Vtama (tapinarof) cream 1% Aryl hydrocarbon receptor agonist Treatment of atopic dermatitis in adults and pediatric patients 2 years of ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...

JERSEY CITY, N.J., November 05, 2024--The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.